JP Morgan maintains Zimmer Biomet Holdings at Neutral, raises price target to $120 from $117
JP Morgan kept its Neutral rating on Zimmer Biomet Holdings but raised its price target to $120 from $117, suggesting a 12.3% upside from the Nov 5 close of $106.85. Recent analyst price targets for the company range from $107 to $125.
How this was made

The 30-second read
Why it matters
The upgrade may generate modest buying pressure, but the small magnitude limits its trading significance.
Market read
A minor analyst upgrade that could produce limited upside for ZBH.
What to watch
Potential supply-chain constraints or upcoming earnings could outweigh the small analyst upgrade.
Background
JP Morgan's analyst note updates the price target for Zimmer Biomet Holdings, reflecting a slight improvement in its valuation outlook.
Ticker impact
JP Morgan raised its price target on Zimmer Biomet Holdings to $120 from $117, indicating a fresh analyst upgrade.
potential modest upside as the market prices in the higher target
The new target is only 2.6% higher and reflects a slight improvement in outlook, likely prompting limited buying interest.
Market effects
May slightly lift the orthopedics/medical devices sector as analysts adjust expectations.
Limited to U.S. equities; no broader regional effect.
Minimal global impact; primarily relevant to investors in ZBH.
Counterpoint
The modest target raise may be insufficient to justify a position given broader market volatility.
Key entities
- companyZimmer Biomet Holdings
Medical device manufacturer whose price target was raised.
- analyst_firmJP Morgan
Issued the new price target.

